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INTRODUCTION
A desire for a “cure for the common cold” has been a
perennial wish from a long-suffering populace. While not uni-
versally considered a high-priority medical need, upper respi-
ratory tract infections (URTIs) cause countless sleepless nights
and are responsible for vast economic losses due to missed
work and school absences. The recent development of im-
proved diagnostic techniques has greatly expanded our knowl-
edge of the agents that cause this ubiquitous clinical syndrome
and has also broadened our understanding of the epidemiology
and medical impact associated with respiratory viruses (RVs)
other than influenza virus.
These developments, however, have proven to be a double-
edged sword for companies that would develop and license
antiviral agents for URTIs. While the increased sensitivity of
PCR-based diagnostics has greatly increased the probability of
identifying the causal offender in patients with URTI, large-
scale molecular screening for viral genome sequences contin-
ues to identify new agents that are also putatively responsible
for this nonspecific clinical syndrome. Accordingly, the devel-
opment of an antiviral with high specificity for a specific agent
(a common goal of drug development programs) effectively
targets an ever-shrinking proportion of subjects with symptoms
of the common cold. Because syndrome-based therapy would
expose many subjects to a drug who do not stand to benefit
from it, the bar for safety of such an antiviral is high. Targeted
therapy based upon the presence of the causative virus would
be preferable; here, a revolution in simple, office-based diag-
nostics for identifying the viral cause of URTIs would signifi-
cantly advance the field.
Here we discuss antivirals for RVs other than influenza virus
(both those available and those currently under development),
considering the epidemiology of such infections, the important
role played by diagnostic testing in treatment, and the hurdles
that are faced in development of these compounds.
TAXONOMY AND ANTIVIRAL TARGETS
Despite commonalities in disease presentation among many
of the RVs, they are genetically and antigenically distinct (Ta-
ble 1). The RNA viruses of the Mononegavirales order contain
single-stranded genomes that are negative sense. This order is
comprised of seven families, including Orthomyxoviridae
(which contains the influenza viruses) and Paramyxoviridae
(which contains the parainfluenza viruses (PIVs), human re-
spiratory syncytial virus [RSV], and human metapneumovirus
[hMPV]). Members of both families are enveloped; unlike
viruses in the family Paramyxoviridae, the viral genomes from
family Orthomyxoviridae are segmented.
The Picornaviridae are nonenveloped viruses with a single-
stranded genome of positive polarity. The rhinoviruses are the
most important members of this family causing respiratory
diseases in humans; other viruses in this group that can cause
respiratory disease are enteroviruses (such as coxsackieviruses
and numbered enteroviruses). Over 100 serotypes of rhinovi-
rus have been identified, a fact that has significantly hamstrung
the development of vaccines for this ubiquitous human patho-
gen. Viruses from the family Coronaviridae also contain posi-
tive-sense single-stranded RNA (ssRNA) but are enveloped.
This family currently includes five members that are known to
infect humans: human coronavirus (HCoV) 229E, HCoV
OC43, the severe acute respiratory syndrome-associated CoV
(SARS-CoV), and the recently described HCoV NL63 and
HCoV HKU1 (174).
DNA viruses associated with human respiratory disease in-
clude the nonenveloped double-stranded DNA (dsDNA) vi-
ruses from the family Adenoviridae and the newly discovered
ssDNA virus from the family Parvoviridae known as human
bocavirus (HBoV).
EPIDEMIOLOGY
Respiratory viral infections are an important cause of mor-
bidity and, in some settings, of mortality as well. For most RVs,
the epidemiology is characterized by annual outbreaks during
the winter and spring seasons; some RVs, however (e.g., PIVs),
are prevalent throughout the year. The epidemiology of RVs in
immunocompromised patients usually parallels that observed
in the community, as these viruses circulate in immunocompe-
tent individuals (including health care personnel, family mem-
bers, and visitors).
The social and economic impact of respiratory viral disease
is substantial. For instance, respiratory viral infections lead to
more than 400,000 hospitalizations per year in children less
than 18 years of age in the United States (81). Using RSV-
specific diagnostic codes alone, an estimated 96,000 RSV hos-
pitalizations occurred annually among children in the United
States in 1997 to 2000 (21).
Immunocompetent Hosts
Seasonal colds. Seasonal colds represent a clinical syndrome
of upper respiratory signs and symptoms, which include rhi-
norrhea, sore throat, sneezing, cough, and watery eyes. None
of the symptoms are pathognomonic for any specific virus, as
virtually all known RVs can cause any combination of these
symptoms. While there are important differences in the symp-
toms between viruses (128, 162), none of these differences are
sufficiently distinct to enable a definitive clinical diagnosis.
Bronchiolitis. Bronchiolitis is the most common cause of
hospitalization of small infants in developed countries (112,
155, 220). RSV is the leading cause of bronchiolitis, but other
RVs such as hMPV, influenza virus, and CoVs, have also been
shown to cause this disease (59, 66, 149; H. Stempel, E. Martin,
J. Kuypers, J. Englund, and D. Zerr, presented at the Infec-
tious Diseases Society of America Annual Meeting, San Diego,
CA, 4 to 7 October 2007.). A recent study showed that lytic
viral infection of the bronchial tissue is the dominant patho-
genic mechanism in children with bronchiolitis (222). Bronchi-
olitis is a cause of hospitalization in approximately 45 of 1,000
infants in the United States, with a rate of 126 outpatient visits
per 1,000 infants (23, 139, 163). Certain populations, such as
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American Indian and Alaska Native infants, have a signifi-
cantly higher incidence (23, 163, 179). Prematurity is an im-
portant risk factor for severe RSV disease in children, but
other factors, including chronic lung disease (e.g., bronchopul-
monary dysplasia), congenital heart disease, and low socioeco-
nomic status, are associated with more severe clinical manifes-
tations. Ethnicity, male sex, and body mass of 5 kg are also
important (179).
Acute otitis and sinusitis. RVs have been increasingly ap-
preciated as causes of acute otitis media and sinusitis. Indeed,
studies in children suggest that RSV is the cause of acute otitis
media in approximately 15% of cases, and it accounts for
one-third of viral causes (158, 176). Other viral causes include
PIV, rhinovirus, adenovirus, enterovirus, and influenza virus
(158). Rhinovirus was the predominant virus recovered in the
middle ear cavities of children with asymptomatic otitis media
with effusion in one study (28). Ear involvement of viral infec-
tions has also been seen in adults (129).
Sinusitis occurs in 10% of adult patients with acute RV
infections (129). RSV, influenza viruses, and picornaviruses
appear to be most commonly involved (129).
Croup. The majority of cases of viral croup are caused by
PIVs. PIV type 1 appears to be more commonly involved than
types 2, 3, and 4 (71, 110, 178). However, RSV, adenovirus,
hMPV, and influenza virus can cause croup as well (43, 166,
231). Recently, CoV NL63 and HBoV have been described as
causes of croup (4, 215).
Community-acquired pneumonia. RVs are increasingly rec-
ognized as a cause of community-acquired pneumonia in
adults, especially the elderly, and children (50). Overall, stud-
ies published to date suggest that up to 20 to 25% of cases of
community-acquired pneumonia in adults are due to RVs (94),
with influenza viruses and rhinoviruses the leading causes. The
median age in the study by Jennings et al. (94), which evaluated
RSV, PIV, adenovirus, rhinovirus, and CoVs in adult patients
with community-acquired pneumonia, ranged from 51 years
for adenovirus pneumonia to 81 years for PIV pneumonia.
RSV, PIV, CoVs, adenovirus, enterovirus, HBoV, and hMPV
have also been described as causes of community-acquired
pneumonia in young immunocompetent adults as well as in the
elderly (3, 53, 71). In addition, adenovirus is a well-known
cause of pneumonia in military recruits (218).
Exacerbation of COPD or asthma. Historically, exacerba-
tions of chronic obstructive pulmonary disease (COPD) have
been thought to be caused by bacterial infection, which pro-
vides the rationale to administer antibiotics empirically. Re-
cent evidence suggests that RVs are an important trigger for
both COPD and asthma exacerbations (173, 183). Studies to
date suggest viral causes in approximately 20% of exacerba-
tions. In addition to influenza A and B viruses, CoVs, rhino-
viruses, RSV, and hMPV are detectable in individuals with
COPD exacerbations (53, 65, 104–106, 186). Persistence of
RSV in the respiratory tract in subjects with COPD has been
shown to be associated with airway inflammation and an ac-
celerated decline in FEV1, thus representing a new potential
target for therapeutic intervention (230) Rhinovirus has been
associated with asthma exacerbations (65). There is a potential
role of early RSV infection in childhood as a risk for subse-
quent asthma development (190).
Immunocompromised Hosts
Though the impact of RVs in the immunocompetent host is
substantial, patients with compromised immune function are
TABLE 1. Classification of and key targets for human respiratory viruses other than influenza virus
Family (nucleic acida) Representative virus Cellular receptor(s) Viral target(s) Cellular targets
Paramyxoviridae ( ssRNA) RSV Sialyl-glycoproteins,
glycolipids
Fusion polypeptide,
RNAi, N protein,
L protein
Severalb
PIV Sialyl-glycoproteins,
glycolipids
HN, RNAi
hMPV Sialyl-glycoproteins,
glycolipids
F protein
Picornaviridae ( ssRNA) Enteroviruses (coxsackievirus
type A or B, echovirus)
ICAM-1, decay-accelerating
factor (CD55), CAR,
integrins
Viral capsid CARc or other cell-
associated factors
Rhinovirus ICAM-1, sialic acid Viral capsid, viral
protease
Coronaviridae ( ssRNA) HCoV CD13 (HCoV 229E), ACE2
(HCoV NL63, SARS-
CoV), CD209L (SARS-
CoV, HCoV-229E)
Several (see the
text)
Adenoviridae (dsDNA) Adenovirus CAR, integrins DNA polymerase CAR or other cell-
associated factors
Parvoviridae ( or  ssDNA) HBoV Unknown (sialyl-
glycoproteins?)
DNA polymerase
a , negative sense; , positive sense.
b See the text.
c CAR, coxsackievirus and adenovirus receptor.
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far more likely to experience poor outcomes on a per-subject
basis. Accordingly, the bulk of clinical data for the use of
antivirals for RV infections has been accumulated from this
population.
Hematologic malignancies and HCT. Among hematopoietic
cell transplant (HCT) recipients and severely immunosup-
pressed nontransplant patients with hematologic malignancies
(229), RSV URTI may progress to fatal pneumonia (73). Dur-
ing the RV season, the incidence of RSV infection may be as
high as 10% (152, 192), though recent advances in infection
control practices have reduced the attack rate at many centers.
In a large study, winter season, male gender, and use of bone
marrow as a stem cell source were identified as risk factors for
the acquisition of RSV in HCT recipients (152). URTI pre-
cedes pneumonia in 80% of patients, and approximately one-
third of patients with RSV URTI progress to pneumonia after
a median of 7 days. The strongest risk factors for progression
to pneumonia are older age and lymphopenia (15, 152).
There is some evidence that low-risk autologous HCT re-
cipients with pretransplant RSV infection may be transplanted
without adverse outcome (5). The outcome of RV infections
may also be less severe with nonmyeloablative or reduced-
toxicity conditioning regimens (J. Schiffer, K. Kirby, B. Sand-
maier, D. Maloney, R. Storb, L. Corey, and M. Boeckh, pre-
sented at the Infectious Disease Society of America Annual
Meeting, Toronto, Ontario, Canada, 12 to 15 October 2006),
highlighting the importance of immune status in disease sever-
ity. Accordingly, pretransplant RSV infection should lead to a
delay of allogeneic myeloablative HCT procedures until clear-
ance of the virus in order to avoid fatal pneumonia during the
time of most severe immunosuppression (161).
hMPV can cause URTI and fatal interstitial pneumonia in
HCT recipients (48). Risk factors for acquisition and progres-
sion are poorly defined.
Of the four types of PIVs, PIV type 3 is most commonly
detected in HCT recipients (90% of cases), followed by se-
rotypes 1 and 2. The incidence of 7% after HCT in two studies
is higher than that reported for RSV (4%) with conventional
detection methods (151, 226). Recent studies using PCR sug-
gest that the incidence may be higher than 15% (162). Only
HCT from an unrelated donor has been identified as a risk
factor for acquisition of PIV (151). In T-cell-depleted patients,
the resulting CD4 lymphopenia has been reported to increase
the risk of all RV infections, including PIV (26). Similar to the
case for RSV infection, URTI is the predominant presentation
of PIV infection in this population. Progression to pneumonia
seems to be less common than with RSV (151). The most
important risk factors for the progression from URTI to pneu-
monia are the use of systemic corticosteriods and lymphopenia
(26, 28, 151). Over half of HCT recipients with PIV 3 pneu-
monia have serious pulmonary copathogens such as Aspergillus
fumigatus (151).
Adenovirus pneumonia can occur in HCT recipients, espe-
cially following in vivo or ex vivo T-cell depletion (56, 121,
241). Adenovirus pneumonia can occur as an isolated event or
as part of disseminated disease and is often associated with
high-level DNAemia (121).
Limited information is available on rhinovirus, CoV, and
BoV infection after HCT (61). These viruses are relatively
frequently detected, but their potential to cause lower respira-
tory tract disease is poorly defined (20, 63). Cases of lower
respiratory tract disease with fatal outcome have been de-
scribed with rhinovirus, often in the presence of copathogens
(20, 63, 92).
SOT. Similar to the case for HCT recipients, RVs can cause
major morbidity and also mortality in solid organ transplanta-
tion (SOT) recipients. Incident infection depends on virus ex-
posure, but the disease severity appears to be different in
different organ transplant settings. The setting with the most
significant impact is lung and heart-lung transplantation, while
liver and renal transplant recipients appear to be somewhat
less affected (164, 191, 224). RVs have been implicated in
pneumonia and chronic rejection in lung transplant recipients
(9, 108, 225). The highest morbidity has been described with
RSV, influenza virus, and PIV; however, there is probably a
diagnostic bias, as more recently discovered viruses have not
been studied to the same extent as these long-known viruses.
For RSV, most data come from lung, renal, and pediatric
liver transplantation. In lung transplant recipients, RSV is as-
sociated with a high frequency of RSV pneumonia and with
subsequent organ rejection and bronchiolitis obliterans (BO);
direct mortality due to RSV infection, however, is low (225).
RSV infections in pediatric liver transplant recipients have
been associated with significant morbidity, including pneumo-
nia (12, 170).
In a large study of lung transplant recipients, 5.3% of pa-
tients had PIV diagnosed by bronchoalveolar lavage or trans-
bronchial biopsy after lung transplantation (217). The onset of
PIV infection was at a median of 2 years posttransplantation
(range of 0.6 to 5 years), and high rates of acute allograft
rejection (82%) and BO (32%) were documented (217).
Adenovirus infection may result in pneumonia, hepatitis,
hemorrhagic cystitis, nephritis, enterocolitis, and disseminated
disease in SOT recipients (91). Incidence figures for adenovi-
rus infection range from 6.5% to 8.3% (88). Patients often
recover without specific treatment (88). However, more seri-
ous manifestations have been reported, including fatal cases of
hepatitis or disseminated infection after liver transplantation
(141); enteritis in small bowel transplant recipients and acute
rejection and adenoviral enteritis in intestinal transplant recip-
ients (97, 156, 168); pneumonia associated with graft loss,
death, or progression to BO in lung transplant recipients (22,
156); and coronary vasculopathy and graft loss after heart
transplantation (187).
Limited data exist on hMPV. In lung transplant recipients,
hMPV infection may present as mild, self-limited infection
(42) or as a serious infection with acute graft rejection (62,
109).
Human rhinovirus infection after SOT generally appears to
be relatively mild, but persistent infection with graft dysfunc-
tion has been described in lung transplant recipients (95, 137).
All four human CoVs may cause pneumonia; however, most
patients appear to clear the virus spontaneously (60, 61). Late
airflow obstruction following CoV infections has been ob-
served in lung transplant recipients; large cohort studies have
not yet been conducted (108).
HIV/AIDS. Compared with that in pediatric cancer patients,
the frequency of RV infections appears to be higher in human
immunodeficiency virus (HIV)-infected patients (as might be
expected because their higher exposure within the at-large
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community), but the clinical course appeared to be less severe
(140). The burden of severe pneumonia due to RSV, influenza
virus, PIV, and adenovirus was substantially higher in South
African children infected with HIV than in non-HIV-infected
children (132, 134, 135). In another South African study, PIV
infection was associated with a higher mortality in HIV-in-
fected children than in uninfected individuals (133). hMPV
was identified as a possible cause of pneumonia in 3.7% of
HIV-infected versus 9.1% of non-HIV-infected children and
was the second most common RV associated with hospitaliza-
tion (after RSV). The incidence and impact of CoV infection
in HIV-infected children have not been systematically evalu-
ated.
Elderly persons. Studies have only recently examined the
full impact of RV infections other than influenza in the elderly.
The best data exist for RSV. In a prospective study, RSV
accounted for 10.6% of hospitalizations for pneumonia, 11.4%
for COPD, 5.4% for congestive heart failure, and 7.2% for
asthma (52). RSV and hMPV have also been reported to cause
outbreaks in chronic care facilities (16, 51).
IMPORTANCE OF DIAGNOSTICS TO
TARGETED THERAPY
One important feature of RV infections is the nonspecific
nature of clinical signs and symptoms. Indeed, there are very
few, if any, specific features that allow clinical diagnosis ac-
cording to causal virus (Table 2). The high number of potential
viral agents that may cause similar symptoms of respiratory
illness presents formidable diagnostic challenges. The absence
of broad diagnostic platforms that are office based and inex-
pensive (as well as the lack of effective outpatient treatment
options) have prevented the widespread use of existing diag-
nostics. Currently, the following diagnostic tests are available.
Culture and Antigen Detection
Standard methods available for testing include viral cultures
(results are available in several days), shell vial centrifugation
cultures using virus-specific monoclonal antibodies (1 to 3
days), direct fluorescent-antibody (DFA) tests (2 h), and en-
zyme immunoassays (2 h). A problem with the rapid test meth-
ods is relatively low sensitivity in adults, where the viral load
may be low (49–51).
Appropriate specimen handling is important for recovery of
the virus via culture. Nasal wash specimens should be placed
on ice or in the refrigerator immediately and transported to the
laboratory without delay (49). Specimen setup in the labora-
tory should occur within 2 to 4 h. Isolation of rhinovirus re-
quires lower incubation temperatures. On tissue sections from
lung biopsy or autopsy specimens, virus-specific monoclonal
antibody staining and viral cultures may be used.
PCR and Microarray Platforms
Molecular detection techniques are rapidly replacing tradi-
tional methods (39, 83, 242). Major efforts are under way to
develop multiplex assays that can detect a large number of
respiratory pathogens concurrently (114, 136, 153). A multi-
plex assay that detects seven RVs (Hexaplex) has shown ex-
cellent performance characteristics in various clinical settings
(83, 98). Another multiplex platform (MultiCode-PLx system;
EraGen Biosciences, Inc., Madison, WI), which detects 17 RVs
simultaneously, showed significantly increased diagnostic yield
compared to DFA or culture methods; this was caused mainly
by improved detection of influenza A virus and viruses not
readily detected by standard virologic methods, including
hMPV, CoVs, and rhinoviruses (153). A 20-RV microbead-
based assay also showed excellent sensitivity and specificity as
well as an increased yield for detection of viruses that are
difficult to detect by culture or DFA (136). Microarray and
nanotechnology are also being explored to develop large-scale
and efficient viral detection platforms (34, 57, 123).
ANTIVIRAL AGENTS: MODE OF ACTION AND
SPECTRUM OF ACTIVITY
A wide variety of strategies have been investigated in an
attempt to interrupt the replication of the RVs, though it is
worth noting that ribavirin is the only FDA-approved agent for
the treatment of RVs other than influenza virus. In this section
we briefly summarize the most promising of those strategies
TABLE 2. Seasonality, symptoms, and diagnosis of infections with respiratory viruses other than influenza virusc
Virus Seasonality
Frequency of disease manifestation Performance of diagnostic technique
URTI Otitismedia Croup Bronchiolitis Pneumonia
Airflow obstruction
and/or wheezing Culture
Enzyme
immunoassay
Fluorescent
antibody/rapid
cultures
PCR
RSV           
hMPV        Research NAa  
PIV type 1         NA  
PIV type 2         NA  
PIV type 3         NA  
PIV type 4         NA  
Adenoviruses           
Rhinoviruses         NA NA 
CoVs        Research NA NA 
HBoV   NDb     NA NA NA 
a NA, not available.
b ND, no data.
c Symbols represent negative results or indicators () or levels of test utility or seasonality or disease manifestation frequency (, , and ).
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and highlight the antiviral activities of agents against the RVs
that are currently marketed.
Inhibitors of Attachment and Entry
The first step in the viral life cycle that is amenable to
interference is the attachment and entry of the virus into the
susceptible host cell. RVs possess surface molecules that are
critical for such attachment (Table 1); such molecules are
frequently the prime antigenic components that elicit host neu-
tralizing antibodies.
Accordingly, pooled human and humanized monoclonal an-
tibody preparations have been developed to prevent (and po-
tentially treat) infections due to RVs, most prominently those
caused by RSV. Animal studies provided the proof of concept,
demonstrating that passively administered polyclonal antibody
preparations could prevent RSV lower respiratory tract infec-
tion when high serum neutralizing titers were achieved (223).
RSV-IG (Respigam; MedImmune Inc., Gaithersburg, MD)
was developed with these observations in mind by selecting and
pooling conventional immune globulin that had high-titer ac-
tivity against RSV. Clinical trials with high-risk infants dem-
onstrated a significant reduction in hospitalizations due to
RSV (68, 69); due to the polyclonal nature of the product, it
also reduced infections due to other RVs and episodes of otitis
media (189). However, this product is no longer manufactured.
The large volumes and prolonged infusion times associated
with RSV-IG spurred development of monoclonal antibodies
with specific activity against RSV. Palivizumab (Synagis;
MedImmune Inc., Gaithersburg, MD), the first monoclonal
antibody approved for clinical use as an anti-infective, is indi-
cated for the prevention of serious lower respiratory tract dis-
ease caused by RSV in pediatric patients at high risk for RSV
disease. Palivizumab targets the F (fusion) glycoprotein of
RSV, preventing RSV binding to cells and the cell-to-cell fu-
sion critical in disease pathogenesis. As a monoclonal prepa-
ration, however, the antiviral spectrum of palivizumab is lim-
ited to RSV.
Small-molecule inhibitors of viral entry are also undergoing
development for the treatment and/or prophylaxis of RV in-
fections. Most human rhinoviruses utilize the intracellular ad-
hesion molecule ICAM-1 for attachment to susceptible cells
within the nasal mucosa. Accordingly, soluble forms of
ICAM-1 (e.g., tremacamra [Boehringer Ingelheim Pharmaceu-
ticals Inc., Ridgefield, CT]) have been investigated as a decoy
to occupy these sites and prevent binding. Capsid binding
agents such as pleconaril (Viropharma Inc., Exton, PA) for
human rhinovirus and fusion inhibitors against RSV (both
discussed further below) are also undergoing development to
prevent viral attachment and entry. However, there are no
currently approved compounds that utilize this mechanism of
action.
Nucleoside Analogues
The majority of approved drugs with antiviral activity act as
nucleoside analogues, which act by inhibiting RV DNA or
RNA polymerases. Specificity is a common issue with this
approach; the compound must have greater affinity for viral
than host polymerase in order to limit toxicities.
Ribavirin. Ribavirin (1--D-ribofuranosyl-1,2,4-triazole-3-
carboxamide) (Virazole; ICN Pharmaceuticals Inc.) is the only
antiviral approved by the FDA for the treatment of an RV
other than influenza virus, that being for the treatment of
hospitalized infants and young children with severe lower res-
piratory tract infections due to RSV. Though available in in-
travenous and oral formulations, for RSV infection it is ad-
ministered as a small-particle aerosol using a tent, mask, or
mechanical ventilator for 12 to 18 h daily or, alternatively, at
higher doses over 2 h given three times daily. The precise
mechanism of action is unknown but appears to be multifac-
eted. As a structural analogue of guanosine, it inhibits the
enzyme IMP dehydrogenase; phosphorylated forms of the
compound inhibit RSV RNA polymerase. Alternative expla-
nations for clinical activity include immunomodulatory effects
(80) or the triggering of lethal mutagenesis of the viral genome
(205). In vitro, ribavirin has broad-spectrum activity against a
wide variety of RVs, including RSV, PIV, and adenovirus
(194); in vitro activity against the human rhinoviruses is vari-
able according to serotype.
Ribavirin was developed first as an influenza drug and
showed impressive reduction of mortality in mouse models of
influenza (232, 238). In human trials, however, results were
mixed (194); as a result, the U.S. Food and Drug Administra-
tion declined to approve the drug for influenza. The absence of
approved agents to treat infections other than influenza has
prompted the off-label use of aerosolized and systemic ribavi-
rin for many RV infections in the immunocompromised host
(as discussed below). Ribavirin’s high cost, mode of delivery,
side effect profile (potential for sudden deterioration of respi-
ratory function when given via aerosol and dose-dependent
anemia when administered systemically), and potential for ter-
atogenicity, however, have restricted widespread use in the
at-large community. Indeed, as discussed below, ribavirin is
rarely used for the only population for which it is FDA ap-
proved: hospitalized infants and young children with severe
lower respiratory tract infections due to RSV.
Cidofovir. Cidofovir [(S)-1-(3-hydroxy-2-phosphonylmethoxy-
propyl)cytosine] (Vistide; Gilead Sciences, Foster City, CA) is
an acyclic nucleoside phosphonate that is converted into its
active metabolite through two consecutive phosphorylation
steps by cellular enzymes. The diphosphate form acts as a
cytosine nucleoside analogue and is used as an alternative
substrate by the viral DNA polymerase, for which it has a
higher affinity than host DNA polymerase. Licensed only for
the treatment of cytomegalovirus retinitis in patients with HIV/
AIDS, it has broad in vitro antiviral activity that includes the
human adenoviruses that cause respiratory illnesses in humans.
However, renal impairment is a major dose-limiting toxicity
with cidofovir; cases of acute renal failure resulting in dialysis
and/or contributing to death have occurred with as few as one
or two doses of cidofovir. As a result, cidofovir has been used
clinically only among patients with severe adenovirus infec-
tions and/or those at high risk for adenovirus-related death
(such as recipients of stem cell transplants), as discussed below.
Immunomodulatory Therapy
IFNs. The antiviral activity of interferon (IFN) has been
known since 1957 (90). dsRNA is a potent inducer of endog-
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enous production of IFN, indicative of its role in modulating
viral infections. IFN acts by inhibiting protein synthesis (and
thus host-directed synthesis of new viral particles), in addition
to stimulating host defense mechanisms, including cellular and
humoral immune responses. IFN- (currently in its preferred
pegylated form) has acquired a definitive place in the treat-
ment of hepatitis C infections in combination with ribavirin.
However, despite pronounced antiviral effects in several an-
imal models of RV infection, topically applied IFN has been
ineffective for the treatment of RV infections such as rhinovi-
rus, as discussed below. With side effects ranging from fever
and malaise to severe thrombocytopenia and suicidality, the
investigation of systemic IFN for the treatment of RV infec-
tions is presently limited to the highly pathogenic SARS-CoV.
Corticosteroids. It is logical that corticosteroids may offer
clinical benefit against the inflammation accompanying RV
illnesses, but data regarding virus-specific responses to steroids
are lacking. A number of randomized controlled trials have
documented the effectiveness of glucocorticoids in relieving
symptoms of croup (11, 180). For bronchiolitis, studies suggest
that approximately 25% of infants hospitalized with this diag-
nosis receive corticosteroids, but the data showing efficacy have
been inconsistent and controversial (40). The most recent large
meta-analysis and a subsequent large randomized trial found
no benefit in bronchiolitis symptoms or length of stay for in-
fants and young children treated with glucocorticoid therapy
compared with placebo (40, 157). Steroids were commonly
employed to treat patients with SARS-CoV; however, the
treatment effects are difficult to interpret in the absence of
randomized trials and because of frequent concomitant use of
other agents (discussed below). There are few data specific to
the immunocompromised host, but the receipt of steroids has
been shown to be a significant dose-dependent risk factor for
progression of PIV type 3 URTI to pneumonia in HCT recip-
ients (151).
Oligonucleotide Approaches (Antisense/siRNA)
RNA interference (RNAi) is a normal cellular process by
which dsRNA causes the silencing of the target mRNA. RNAi
thus represents a normal posttranscriptional mechanism that
leads to “knockdown” of gene expression. RNAi via the use of
synthetic small interfering RNAs (siRNAs) holds the promise
of specific antagonism of intrinsic host-derived disease-causing
genes or of reducing the production of viral genomes. The
therapeutic potential for RNAi as an antiviral strategy is par-
ticularly great, as the absence of host and viral gene homology
ensures antiviral specificity. In addition, siRNAs hold an ad-
vantage over protein therapeutics given their ease of synthesis
and the rapidity with which lead compounds can be identified
and optimized. Like with protein therapeutics, delivery issues
pose the greatest hurdle; topical application of siRNAs to the
nasal or pulmonary mucosa may need to be coupled with
techniques that allow intracellular penetration for antiviral
efficacy. Potent prophylactic and therapeutic efficacies in
mouse models of RSV and PIV have prompted further clinical
development of this approach (discussed below).
While not the subject of this review, several alternative ap-
proaches have also been considered to decrease the impact of
RV infections. Biopsy of the nasal mucosa after experimental
challenge with human rhinovirus reveals that infection with
this common RV occurs in a small number of cells which retain
their cellular integrity (169). These observations suggest that it
is the host response to infection, rather than virus-induced
cellular damage per se, that explains symptoms attributed to
incident rhinovirus infection. Accordingly, approaches to sup-
press inflammation may have merit for certain RV infections in
the immunocompetent host; combined antiviral and anti-in-
flammatory therapy may be required to effect the greatest
clinical benefit in these patients.
THERAPY FOR SPECIFIC VIRAL INFECTIONS
RSV
Two drugs are approved for the management of RSV infec-
tion in the United States. Ribavirin is approved for the treat-
ment of RSV bronchiolitis in children, while palivizumab is
approved for prevention of RSV-associated hospitalization for
high-risk infants.
Ribavirin. A recent Cochrane database review of ribavirin
for RSV infection of the lower respiratory tract in young chil-
dren showed a significantly shorter duration of mechanical
ventilation and trends toward reduced mortality, less respira-
tory deterioration, shortened overall hospitalization, and a de-
crease in the long-term incidence of recurrent wheezing (216).
However, another recent systematic review found that there
was no evidence that ribavirin use led to consistent or more
than transient improvements in clinical outcomes (101). Sev-
eral problems were noted with the studies of aerosolized riba-
virin for severe bronchiolitis, including small sample sizes and
the absence of benefit for clinically meaningful outcomes (such
as duration of hospitalization or duration of illness). The one
study that did report differences in duration of mechanical
ventilation and hospitalization (193) has been criticized for
using sterile water in the placebo arm, which is a possible
irritant to the airways compared with standard mechanical
ventilation with humidified air. A further double-blind trial of
aerosolized ribavirin that used an isotonic saline solution as the
placebo could not demonstrate a positive effect of ribavirin on
the same outcomes (138). Accordingly, the American Acad-
emy of Pediatrics currently recommends that ribavirin should
not be used routinely in children with bronchiolitis, citing the
“marginal benefit for most patients” and the “cumbersome
delivery requirements, potential health risks for caregivers, and
high cost” that serve as disincentives for use (2).
Since untreated RSV pneumonia may be associated with a
high fatality rate in post-HCT patients and those with under-
lying hematologic malignancies (30, 73), however, ribavirin is
used more frequently in these settings. Data supporting the use
of ribavirin in immunocompromised patients are primarily in
the form of nonrandomized studies. Intermittent, short-dura-
tion (2 g over 2 h three times per day), or continuous aerosol-
ized ribavirin is considered the treatment of choice for RSV
pneumonia in severely immunosuppressed patients, including
allogeneic HCT recipients following myeloablative condition-
ing. With this regimen, the 30-day all-cause mortality is ap-
proximately 40% (128, 152); however, if treatment is started
after respiratory failure, the outcome is almost uniformly fatal
(228). There are several factors that may account for differ-
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ences in outcome in the available cohort studies. Perhaps the
most important factor is the timing of therapy initiation (128).
Other factors such as the presence of lymphopenia at the time
of diagnosis (15, 30, 125), the presence of copathogens (e.g.,
invasive molds or cytomegalovirus), and the use of immuno-
suppressive agents are also likely to be important. Systemic
(e.g., oral and/or intravenous) ribavirin alone does not seem to
be effective for the treatment of pneumonia, although studies
are small in size (117, 196). Systemic ribavirin given at the
URTI stage may be more effective (185). Whether combined
oral and aerosolized ribavirin is more effective than aerosol-
ized ribavirin alone has not been studied.
Due to the high mortality associated with RSV pneumonia
in this population, aersolized ribavirin has also been used pre-
emptively for immunosuppressed patients with RSV URTI to
prevent progression to pneumonia (30). A small randomized
trial suggests that this approach is safe and that ribavirin re-
duces RSV viral load (14). Whether progression to pneumonia
can be prevented by this approach remains an open question.
Immunoglobulin preparations and palivizumab. Palivizumab
is an RSV-specific humanized monoclonal antibody that is li-
censed for use in at-risk pediatric patients. It has a long serum
half-life, enabling its administration by intramuscular injection
at monthly intervals during the RSV season. The pivotal ran-
domized controlled trial with premature infants (35 weeks
gestation) and pediatric subjects with underlying bronchopul-
monary dysplasia showed that palivizumab reduced hospital-
izations due to RSV infection by 55% (10.6% with placebo
versus 4.8% with palivizumab), though hospitalizations were
reduced by a greater degree for premature infants than for
those with bronchopulmonary dysplasia (89). A subsequent
randomized study of subjects with congenital heart disease
demonstrated that palivizumab also decreased the rate of
RSV-related hospitalization by 45% (from 9.7% for placebo
recipients to 5.3% for the palivizumab group) (54). As recently
reviewed by Cardenas et al., several postmarketing surveillance
studies have confirmed the utility of palivizumab prophylaxis in
these patient populations (25).
Despite the high attack rate and high mortality, there is no
consensus on the role of antibody preparations, including
palivizumab, in immunocompromised patients; this may be
due to the large volumes (and thus high cost and questionable
cost-effectiveness) required for adult prophylaxis. Uncon-
trolled data suggest that high-titer antibody preparations or
palivizumab may be required if such adjunctive therapy is given
(13, 46, 196). Nevertheless, palivizumab prophylaxis before
and after HCT is often used in small children, analogous to its
use in high-risk infants. Palivizumab is also used in combina-
tion with aerosolized ribavirin for treatment of documented
pneumonia due to RSV in severely immunocompromised chil-
dren and adults (13).
Drugs in development for RSV. Four compounds are in early
clinical development for RSV infection. RSV-604 (A-60444)
(Novartis, Basel, Switzerland) is a novel oral benzodiazepine
that inhibits the RSV N protein (29). The compound is under-
going phase I/II testing in transplant recipients. The novel
fusion inhibitor TMC353121 (Tibotec Pharmaceuticals,
Mechelen, Belgium) is also undergoing phase I testing in stem
cell transplant recipients (J. Bonfanti, T. Gevers, C. Meyer, P.
Timmerman, R. Willebrords, P. Van Remoortere, P. Wiger-
inck, and K. Andries, presented at the 47th Interscience Con-
ference on Antimicrobial Agents and Chemotherapy, Chicago,
IL, 17 to 20 September 2007). Another fusion inhibitor is RS
637, also known as VP14637 (RSVCO, Inc., Gaithersburg,
MD); the compound is in late-stage preclinical development.
BTA9881 is an F-protein inhibitor under phase I clinical de-
velopment by Biota/MedImmune (131). siRNAs (Alnylam
Pharmaceuticals, Cambridge, MA) have also been developed
for aerosol delivery (45); ALN-RSV01 is presently undergoing
phase II testing in adults experimentally infected with RSV.
With regard to prophylaxis, MedImmune (now Astra Zeneca,
London, United Kingdom) has recently developed motavi-
zumab, a next-generation monoclonal antibody for RSV that
was engineered to have increased potency compared to palivi-
zumab. In vitro, motavizumab binds to the RSV F protein
70-fold better than palivizumab, and it was selected from
among other candidates due to its favorable pharmacokinetics
and lung penetration (236). In cotton rats, motavizumab was
approximately three- to fourfold more potent in reducing RSV
titers in the lung than palivizumab; unlike palivizumab, it was
also able to significantly reduce viral titers in the upper respi-
ratory tract (236). In a recently completed phase III pivotal
study of 6,600 infants at high risk for serious RSV infection,
motavizumab reduced the incidence of hospitalization due to
RSV infection by 26% and achieved a 50% reduction in the
incidence of RSV-specific medically attended outpatient lower
respiratory infections compared to palivizumab; no differences
in adverse effects were reported (X. Carbonell, G. Losonsky,
M. Hultquist, E. Connor, et al., presented at the Pediatric
Academic Societies’ Annual Meeting, Toronto, Ontario, Can-
ada, 5 to 8 May 2007). Given its effectiveness in the cotton rat
model, MedImmune is also currently exploring the use of mo-
tavizumab for the treatment of children who are hospitalized
with RSV infection.
Adenovirus
Adenoviruses are associated with a wide variety of illnesses,
including epidemic respiratory infections in closed populations
(such as military recruits). In the absence of vaccination, a safe
and effective antiviral would be welcomed for these popula-
tions; however, currently available agents do not have favor-
able risk/benefit ratios for an illness that is usually self-limited.
Antiviral therapy for adenovirus infections is thus utilized pri-
marily in the severely immunocompromised host for whom the
risk for adenovirus-related mortality is high. Though no agents
have been approved for the treatment of adenovirus infection,
cidofovir and ribavirin have activity in vitro; clinical experience
with these agents is summarized below.
Ribavirin. Clinical responses to ribavirin therapy among se-
verely immunocompromised hosts with established adenovirus
infections have been disappointing (126); this perhaps is at-
tributable to the finding that ribavirin activity in vitro may be
restricted to subgroup C isolates (143). Preemptive therapy, in
which high-risk subjects are monitored for the presence of
early adenovirus infection by PCR of the plasma and treated
with antivirals before symptoms emerge, has also been at-
tempted with ribavirin: one group reported virologic responses
with preemptive ribavirin alone or ribavirin plus cidofovir in 21
of 26 children treated in this fashion, with five deaths (19%)
VOL. 21, 2008 RESPIRATORY VIRUSES OTHER THAN INFLUENZA VIRUS 281
 at Fred Hutchinson Cancer Research Center - Arnold Library on O
ctober 27, 2008 
cm
r.a
sm
.o
rg
D
ow
nloaded from
 
attributed to disseminated adenovirus disease in the absence of
immunologic recovery (96).
Cidofovir. Cidofovir appears to be more clinically active
than ribavirin (147). Administered intravenously, two cidofovir
dosing regimens have been used for the management of ad-
enoviral disease: a “high-dose” regimen of 3 to 5 mg/kg weekly
for several weeks followed by every-other-week dosing (in line
with the approved schedule for the treatment of cytomegalo-
virus retinitis) or a lower-dose, “renal-sparing” regimen of 1
mg/kg three times per week (115, 148, 150, 219, 241). A recent
review of the literature identified 70 HCT recipients with def-
inite or probable adenovirus disease who were treated with2
doses of cidofovir; the overall mortality was 19% among these
subjects (150). A noncomparative cohort study of cidofovir
given with the low-dose protocol showed that it was safe and
potentially effective for the treatment of adenovirus hemor-
rhagic cystitis in HCT recipients, with clinical improvements in
71% of patients (148). Preemptive therapy with cidofovir has
also been attempted; a recent cohort of 177 highly immunosup-
pressed pediatric recipients of allogeneic stem cell transplantation
treated with this strategy had only 2% adenovirus-associated mor-
tality (241). However, the most immunosuppressed subjects
(e.g., those who have received T-cell-depleted HCT) may still
fail to control adenovirus viremia and succumb to adenovirus
disease despite active surveillance and preemptive therapy
with cidofovir, as seen in a recent series of patients from
Vienna, Austria (122).
The most problematic issue with cidofovir remains its toxic
effects on renal function, particularly when given to transplant
recipients, who very commonly receive concomitant nephro-
toxic medications. In one large series of HCT recipients
treated with cidofovir for adenovirus infection, approximately
one-third of subjects developed treatment-emergent renal tox-
icity (127).
Recently, lipid esters of both cidofovir and a related com-
pound, HPMPA [(S)-9-(3-hydroxy-2-phosphonylmethoxypro-
pyl)-adenine], have been developed that have promise for the
treatment of adenovirus, poxvirus, and human herpesvirus in-
fections (116, 175). Interestingly, these compounds appear not
only to have resolved the issues surrounding oral bioavailability
but also to have a lower potential for nephrotoxicity than
cidofovir itself due to reduced distribution to the kidney (36).
High antiadenovirus activity of these compounds has been
demonstrated in vitro (147).
Human Rhinovirus
Despite intensive research and development efforts, there
are no agents approved for the treatment or prevention of
human rhinovirus infections. Investigational approaches to
date have included IFNs, inhibitors of viral attachment and
entry, and inhibitors of viral protease. In the following sections,
we also briefly summarize studies of the use of zinc and echi-
nacea for treatment of the common cold.
IFNs. Several studies have evaluated the efficacy and safety
of intranasal recombinant IFN- 2b in the prevention or treat-
ment of human rhinovirus infections. While modest efficacy
was shown with prophylactic use (74, 197), long-term intrana-
sal administration of natural or recombinant IFN was associ-
ated with nasal irritation that appears to be preceded by IFN-
induced mucosal histologic changes, particularly lymphocytic
infiltration (79). Moreover, treatment of symptomatic rhinovi-
ral infections with intranasal IFN was ineffective (77). Devel-
opment of these compounds has thus halted.
Attachment and entry inhibitors. Tremacamra (Boehringer
Ingelheim, Ridgefield, CT) was a soluble form of ICAM-1 that
was designed to interfere with the attachment of rhinovirus to
endogenous ICAM-1 on target host cells. Intranasally applied
tremacamra demonstrated small but statistically significant ef-
fects on symptom scores when given either before or after
experimental challenge with human rhinovirus (213); clinical
drug development did not progress, however, due to concerns
about efficacy (when given more than 12 h after viral chal-
lenge) and patient acceptability (given the six-times-daily ad-
ministration schedule).
Several capsid binding agents have been designed and have
undergone clinical evaluation. The “WIN” series from the leg-
acy Sterling Winthrop Pharmaceuticals was the first to be ex-
tensively studied; WIN51711 failed to progress due to drug-
induced crystalluria in human volunteers, while WIN54954
demonstrated poor efficacy after experimental challenge, likely
due to poor drug levels at the nasal mucosa (159). Pleconaril
(WIN63843) was subsequently developed and was the first
rhinovirus-targeted antiviral submitted for approval to the U.S.
FDA. In two phase II studies of 1,024 immunocompetent sub-
jects who were treated within 36 h of the onset of symptomatic
URTI, pleconaril reduced the time to resolution of symptoms
by 1 to 1.5 days in the subgroup of subjects (42%) with proven
rhinoviral infections (75). Comparable results were observed in
the 65% of subjects (n  1,363) who were positive for picor-
navirus in the placebo-controlled phase III studies (75).
Though the magnitude of clinical benefit appeared to be small,
these effects were projected to have enormous economic ben-
efits in terms of recouping lost productivity due to sick leave
(142). However, subsequent prophylaxis studies demonstrated
that pleconaril was a cytochrome P450 inducer, which led to
intermenstrual bleeding and pregnancy in some women who
took the drug together with oral contraceptives (55, 76). Con-
cerns for this and other drug interactions and transmitted drug
resistance (167), in addition to the modest efficacy, prompted
the Antiviral Drugs Advisory Committee of the FDA to vote
against a recommendation for approval in 2002. Schering-
Plough (Kenilworth, NJ), under license from Viropharma, has
reformulated pleconaril for intranasal delivery and resumed
development.
Protease inhibitors. A virus-encoded 3C protease is critical
for rhinoviral replication, and thus presents a rational target
for drug development. Rupintrivir (AG7088) was developed as
an intranasally administered 3C protease inhibitor with dem-
onstrated potent activity in vitro against all human rhinovirus
serotypes (160); it demonstrated moderate antiviral and clini-
cal efficacy after experimental human challenge (78). Lack of
efficacy in natural infection studies, however, led to termina-
tion of further development (159). Compound 1 was subse-
quently identified as an orally bioavailable inhibitor of 3C
protease; though safe and well tolerated in phase I studies with
healthy volunteers, further clinical development of this com-
pound is not planned, likely due to marginal pharmacokinetics
(159).
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Zinc and echinacea. Zinc salts have long been known to be
weak inhibitors of rhinovirus replication in vitro (107), possibly
by the binding of zinc ions to rhinovirus surface canyons, thus
inhibiting viral interaction with its surface receptor (154). The
results of individual studies of oral zinc salts have been con-
flicting, and meta-analyses of clinical trials have shown no
evidence of benefit (93). Perhaps this is unsurprising, since
serum zinc concentrations are well below those required for a
direct antiviral effect. However, trials of intranasally applied
zinc have also shown mixed results (8, 145, 211). Preparations
of echinacea are also widely used for the prevention and treat-
ment of the common cold, with results that have been as varied
as the number and nature of the preparations (212). A recent
meta-analysis has concluded that though there is some evi-
dence that preparations based on the aerial parts of Echinacea
purpurea might be effective for the early treatment of colds in
adults, results are not fully consistent (120).
HCoV
There is no specific antiviral therapy available for HCoV
infections. The emergence of SARS-CoV has triggered the
largest thrust of antiviral research for CoVs; therefore, we will
review antivirals specific to SARS-CoV (67).
The sudden and severe nature of the SARS outbreak in 2002
and 2003 necessitated the use of empiric treatment strategies.
A number of antiviral agents have been used to treat SARS,
including ribavirin, lopinavir-ritonavir, and oseltamivir, but
none were given in a controlled fashion, and the efficacy of
these drugs has not been established. CoVs rely on a main
3C-like proteinase to process viral polyproteins for replication,
which provides a prime target for the development of antivi-
rals, aided by knowledge of the crystal structure (240). The
polymerase, helicase, spike protein, and other proteases offer
additional drug targets.
Ribavirin. Although ribavirin has not been shown to effec-
tively inhibit SARS-CoV replication at high concentrations in
Vero cells (38, 201), the use of other SARS-CoV-permissive
animal and human cell lines has demonstrated inhibition of
viral replication, particularly when ribavirin was used in com-
bination with type I IFN (144). A number of reports describe
the clinical use of ribavirin during the SARS outbreak. Al-
though ribavirin was often administered, most studies em-
ployed other agents, including steroids and IFNs, making it
difficult to determine specific antiviral effects of ribavirin (85,
113, 165, 209, 210, 221, 244). A recent systematic review of 30
studies describing the use of ribavirin treatment for SARS
determined that 26 studies were inconclusive regarding treat-
ment efficacy and that 4 publications presented evidence of
possible harm (200). Hemolytic anemia, liver dysfunction, and
electrolyte abnormalities were the main adverse events de-
scribed, although the lack of control groups and concomitant
treatment with other drugs make it difficult to determine cau-
sality (18, 103, 204, 233).
Protease inhibitors. The protease inhibitor combination
lopinavir-ritonavir has been shown to have in vitro antiviral
activity against SARS-CoV (31, 35). Two main clinical studies
evaluated the effects of lopinavir-ritonavir during the SARS
outbreak, which suggest that initial treatment with this drug
was associated with a significantly lower risk of death and
development of acute respiratory distress syndrome than con-
trol treatment (27, 35). However, the antiviral effect was con-
founded by possible bias in the selection of the control group
and treatment allocation (27, 35, 200). Other protease inhibi-
tor compounds have been shown to inhibit SARS-CoV repli-
cation in vitro, including nelfinavir and calpain inhibitors (7,
239).
Attachment, entry, and fusion inhibitors. The membrane-
associated carboxypeptidase angiotensin-converting enzyme 2
(ACE2) is a cellular receptor for SARS-CoV and interacts with
the spike protein (119). ACE2 binding agents, neutralizing
antibodies, or soluble forms of the receptor therefore offer
options for candidate drugs (41, 87, 203). In animal models,
administration of immune serum and monoclonal antibodies
have demonstrated a reduction in SARS-CoV replication and
reduced severity of disease (177, 202, 208). Data from clinical
studies during the SARS outbreak using either convalescent
plasma or intravenous immune globulin were inconclusive with
regard to a beneficial effect (33, 84, 195, 200, 221). Fusion
inhibitors against the SARS-CoV spike protein are also prom-
ising therapeutic candidates (19, 102, 124). Another target is
cathepsin L, a lysosomal protease, which has been shown to
be required for in vitro SARS-CoV infection. Inhibitors of
cathepsin L blocked infection by SARS-CoV, but not HCoV-
NL63, of ACE2-expressing cells (86, 188).
Steroids and IFNs. Systemic steroids were used extensively
for therapy during the SARS outbreak in 2002 and 2003, gen-
erally in combination with ribavirin. Due to this concomitant
drug use, it is difficult to determine whether steroids had a
beneficial effect, and most studies are deemed inconclusive
(200). Type I IFN compounds have been shown to inhibit
SARS-CoV virus replication in vitro and in vivo in animal
models (6, 37, 70, 82, 201, 206). IFN- was shown to be more
potent than IFN-, and synergistic effects were reported for
IFN- with ribavirin, IFN- with ribavirin, and IFN- with
IFN- (31, 144, 181, 182, 198). Two reports described the use
during the SARS outbreak of IFN- given with steroids and/or
ribavirin, but the results in both cases are confounded by
choice of control group, treatment bias, and lack of consistent
treatment regimens (130, 244).
Other. The use of siRNAs targeting the spike gene and
replicase 1A gene of SARS-CoV has inhibited gene expression
and viral replication in SARS-CoV-infected cells (127, 243)
and shown efficacy in SARS-CoV-infected macaques (118). In
vitro studies suggest that additional compounds, such as gly-
cyrrhizin (a component of licorice roots) (38), nitric oxide (99),
niclosamide (235), cinanserin (a serotonin antagonist) (32),
adamantane-derived bananins (207), and plant lectins (100)
inhibit in vitro SARS-CoV replication. Existing drugs, natural
products, and synthetic compounds continue to undergo high-
throughput testing for evidence of anti-SARS CoV activity.
PIV, hMPV, and HBoV
There are no agents approved for the treatment of the PIVs,
hMPV, or HBoV. Ribavirin is active against PIV in vitro and
in animal models (64) and has thus been used for the treatment
of pneumonia in immunocompromised hosts. Only anecdotal
reports of the benefit of aerosolized or systemic ribavirin have
been published; responses have been highly variable, reflecting
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the confounding effects of illness severity, level of immunosup-
pression, and underlying disease (47, 58, 151, 227, 234). In-
deed, in retrospective series of HCT recipients treated with
aerosolized ribavirin with or without intravenous immunoglob-
ulin, mortality was similar among subjects treated with ribavi-
rin and those who were given only supportive care (151, 227).
Promising targets for drug development exist, however; the
viral hemagglutinin-neuraminidase (HN) that mediates bind-
ing and the adjacent fusion protein that HN activates after
binding has occurred are particularly interesting targets. Now
that the three-dimensional crystal structure for the human PIV
type 3 HN has been elucidated (111), structure-function map-
ping is under way (171, 172) and HN inhibitors are being
screened and tested in animal models. A novel HN inhibitor
has been shown to effectively inhibit cell binding, neuramini-
dase activity, and growth of PIVs in tissue culture and in the
lungs of infected mice (1). In addition, RNAi represents a
promising strategy for PIV infections (10).
Though no agents are currently in development for the
treatment of hMPV infections, ribavirin has shown activity in
vitro (237) and in mouse models (72). Antibodies directed
against the hMPV F protein have also been shown to protect
hamsters against infection with hMPV (214), suggesting that
passive immunoprophylaxis (analogous to that used for RSV
infection) could be used to prevent severe hMPV infections in
infants at greatest risk. As for RSV and PIV, RNAi may be an
option for therapy of hMPV infections in the not-too-distant
future (146).
Antivirals active against HBoV have not been described to
date.
FUTURE DIRECTIONS
Given the high burden of disease in both immunocompetent
and immunocompromised hosts, there remains a clear unmet
medical need for antiviral drugs that target RV infections. The
lack of rapid, sensitive, and inexpensive diagnostic tests that
can distinguish a wide variety of respiratory pathogens at the
point of care has been a key factor in slowing down interest in
drug development. The absence of diagnostic platforms makes
it difficult and time-consuming to assess the true burden of
disease in various settings, but perhaps more importantly, it
also restricts the ability to conduct clinical trials in settings
other than highly specialized transplant centers. Although
studies with transplant recipients are feasible, they are complex
due to slow enrollment and are difficult to interpret due to
confounding by underlying disease. Fortunately, recent tech-
nologic advances make it more likely that rapid and affordable
multiplex testing will soon be available at the point of care,
where the burden of disease is the greatest. Also, a recently
developed human volunteer infection model for RSV has
shown consistent infection rates and clinical disease following
standardized inoculation (J. Devincenzo, J. Cehelsky, R. Mey-
ers, A. Vaishnaw, S. Nochur, K. Foote, T. Wilkinson, P. Meek-
ing, A. Mann, E. Moane, J. Oxford, R. Studholme, P. Dorsett,
and R. Lambkin-Williams, presented at the 47th Interscience
Conference on Antimicrobial Agents and Chemotherapy, Chi-
cago, IL, 17 to 20 September 2007). Proof-of-concept testing of
new antiviral compounds in settings other than transplant
recipients may thus become easier; it is hoped that this will
stimulate drug discovery and development.
There are also other ways to address the broad spectrum of
possible pathogens that can cause clinical disease. One is the
development of broad-spectrum antivirals. While respiratory
symptoms are characteristically nonspecific and the spectrum
of possible agents in cases of bronchiolitis, COPD exacerba-
tion, or pneumonia is large, there are clearly a few pathogens
that are both virulent and common. These may include RSV,
PIVs, and possibly hMPV and the recently described CoVs.
While these viruses do not share targets that are amenable to
inhibition by a single small molecule, the use of combinations
of safe and specific agents (including topically or systemically
administered antibodies or siRNA) could be envisaged as a
future approach.
Several alternative approaches are also possible. Nonspecific
potentiators of the host response could be investigated, the
failure of topical IFN notwithstanding. On the other hand,
nonspecific attenuators of the host response (e.g., novel anti-
inflammatory agents such as Toll-like receptor or chemokine
antagonists) could be more effective than current analgesics in
providing symptomatic relief from the common cold. Unfortu-
nately, such immune modulation is not likely to be effective for
those who are already immunocompromised.
Given that vaccines are not available for RVs other than
influenza virus (and are not likely to be forthcoming for rhi-
novirus, the most prevalent etiologic agent, due to the multi-
tude of serotypes), it is hoped that discovery and clinical de-
velopment efforts continue for agents that may treat and
prevent this common human condition, the “common cold.”
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